Olema Oncology is a leading brand dedicated to revolutionizing the standard of care for women living with cancer. With a deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, we strive to develop more convenient and effective therapies for patients. Our mission is powerful, and our goals are big.

One of our groundbreaking products is palazestrant (OP-1250), a Complete Estrogen Receptor Antagonist (CERAN) and selective ER degrader (SERD). This orally bioavailable treatment targets ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. By taking a comprehensive approach to therapy, we aim to address the vulnerabilities that arise from cancer cells' adaptability and mutations.

At Olema, we challenge ourselves to improve the lives of others. Our dedication to developing targeted therapies stems from our unwavering focus on advancing breast cancer therapy. Join us as we continue to design innovative treatments and make a meaningful impact on the lives of women battling cancer.

Stay updated with the latest news and advancements in our pipeline by visiting our website